Astellas pays $760M for Alzheimer's program

Published on Friday 25 April 2008 - 12:59

Summary :
Another day, another big biotech deal. This time it's Japan's Astellas Pharma, which is paying $760 million for access to CoMentis's Alzheimer's drug. The development and commercialization...
Read more

Information source

http://www.fiercebiotech.com/news/frontpage

Website description
Get the latest news on the biotech industry, biotech companies, FDA approval and clinical research. Sign up today for the biotech industry

Articles published on this website : 1 / 7 days - 6 / 30 days

Satori gains $22M to push Alzheimer's work Myriad's Meldrum picked as best biotech CEO Lundbeck preps Phase III trials for alcoholism Elan closes sites, cuts jobs Elan's Martin: Worst biotech CEO?

Other articles published on other websites on the same day

Kurzmeldungen am Freitag, 25.4.08 http://www.scienceticker.info/ Alzheimer's Drug May Be Tested on Humans in Two Years http://www.fdanews.com/ Proteasomes, may Provide a Breakthrough in Treating Alzheimer's and Other Brain Diseases http://www.medindia.com/ Experimental Alzheimer’s Drug Show Promise http://www.redorbit.com/ Black, Hispanic Caregivers More Likely To Misinterpret Signs Of Alzheimer's, Survey Finds http://www.medicalnewstoday.com/ New approach might strike at the core of Alzheimer’s disease http://www.sciencenews.org/ Scientists May Have Found Drug to Treat Alzheimer s http://www.efluxmedia.com/ Targeting Cell Membrane RAFTS Offers Novel Approach To Treat Alzheimer's And Other Diseases http://www.medicalnewstoday.com/ Cutting Edge Genome Technologies And Applications: Advances In Diagnosing, Treating More Diseases http://www.medicalnewstoday.com/ Study Details New Molecular Approach to Preventing Alzheimer's http://www.medicinenet.com/